Pharmaceutical News

RSS

SOHM launches 26 branded generic pharmaceutical products in India

SOHM, Inc., a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, announced today the launch of 26 branded generic pharmaceutical products in India. The Company has already appointed two distributors in Northern India covering the largest state of India with a population of almost 1.5 billion people.

28 Sep 2009

UNC awarded $8.6M for a new Center for Integrated Systems Genetics

Autism, depression, anxiety. Antipsychotic drug side effects. What are the genetic and environmental factors that underlie and contribute to these complex problems? And how do genes and environment interact to shape them?

28 Sep 2009

MarkMonitor Brandjacking Index reveals growth in pharmaceutical brandjacking for popular drug brands

MarkMonitor®, the global leader in enterprise brand protection, today released the company’s latest Brandjacking Index®, which finds a parallel online system of pharmaceutical supply and demand fueled by continued growth in listings for pharmaceuticals on business-to-business (B2B) exchange sites as well as increased traffic to illicit pharmacies. The report also reveals a growth in pharmaceutical brandjacking for popular drug brands.

28 Sep 2009

Merck to distribute Afluria in the U.S. for CSL Biotherapies

CSL Biotherapies and its parent company, CSL Limited, one of the world's leading manufacturers of influenza vaccine, have reached an agreement with Merck & Co., Inc. on rights to market and distribute Afluria® in the United States under an exclusive, six-year agreement effective September 3, 2009.

28 Sep 2009

European Commission grants conditional marketing authorization for Gilead's Cayston

Gilead Sciences, Inc. announced today that the European Commission has granted conditional marketing authorization for Cayston® 75 mg powder and solvent for nebuliser solution (aztreonam lysine) for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF) aged 18 years and older.

28 Sep 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

Presentations on Inovio Biomedical's electroporation-delivered DNA vaccines

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today it will make multiple presentations at the Vaccine 3rd Global Congress being held in Singapore October 4th – 6th.

28 Sep 2009

WellPoint covers administration costs for H1N1 vaccines

Each year, influenza causes illness, hospitalizations and deaths, and severely strains the health care delivery system. This year, seasonal flu is complicated by the emergence and rapid spread of the H1N1 virus. In an effort to ensure that individuals and their families can take the appropriate actions to help protect themselves against the H1N1 virus, WellPoint's affiliated health plans will cover the administration of the H1N1 vaccine without co-pay or deductible for all health plan members. Plans also are encouraging self-insured employers to cover the cost of the vaccination for their employees.

28 Sep 2009

Merck, Qiagen pledge cervical cancer tools at CGI, meeting highlights effects of gender inequality

Drugmaker Merck & Co. announced Wednesday at the Clinton Global Initiative's (CGI) annual meeting in New York that it will "donate more than $500 million of its Gardasil cervical cancer vaccine" with the goal of improving women's health in developing countries, Bloomberg reports.

From QIAGEN Manchester Limited 28 Sep 2009

FDA grants accelerated approval for Allos Therapeutics’ FOLOTYN

Allos Therapeutics, Inc. (Nasdaq:ALTH) today announced that last night the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYNTM (pralatrexate injection) for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

28 Sep 2009

Quintiles Transnational enter into marketing agreement with Allergan for SANCTURA XR

Quintiles Transnational Corp. and Allergan, Inc. (NYSE: AGN) today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR® (trospium chloride extended release capsules), an anticholinergic approved for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency, predominantly to primary care physicians in the United States.

28 Sep 2009

H1N1 vaccine for limited supply only to people at highest risk

The novel H1N1 virus (Swine Flu Virus) is expected to complicate the 2009/2010 flu season. The H1N1 vaccine has been approved for release but availability and access is still unknown. Seasonal influenza vaccine (flu shot) is available and the CDC recommends vaccination over the next few months.

28 Sep 2009

WHO Asia-Pacific Countries pledge to use artemisinin with other drugs by 2015 to prevent drug-resistance

On Wednesday, nine of the 10 countries in the WHO's Asia-Pacific region "that suffer most" from malaria pledged to phase out the use of artemisinin-only to treat malaria and use it in combination with other drugs by 2015, Reuters reports (Lyn, 9/23).

28 Sep 2009

Rosiglitazone slows progression of cachexia in cancer affected mice

Insulin resistance, the hallmark of type 2 diabetes and a condition often associated with obesity, is paradoxically also an apparent contributor to muscle wasting and severe fat loss that accompanies some cancers, according to new research.

27 Sep 2009

Cantwell amendment will raise cost of prescription drugs: PCMA

“America’s pharmacy benefit managers (PBMs) believe strongly in the principle of transparency and empowering payers to make informed health-care purchasing decisions resulting in lower prescription drug costs and higher quality. Regrettably, today’s amendment moves the health care system in the opposite direction.”

26 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

European CHMP recommends marketing approval for Sanofi-aventis' Multaq

Sanofi-aventis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq(R) (dronedarone - 400mg Tablets).

26 Sep 2009

Teva to market generic version of AstraZeneca's antipsychotic agent Seroquel tablets

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a July 1, 2008 decision by the District Court to grant AstraZeneca’s motion for summary judgment of no inequitable conduct related to U.S. Patent No. 4,879,288.

26 Sep 2009

GenVec to receive $2.3M from NIAID for HIV vaccine candidate production

GenVec, Inc. announced today that the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), has executed its third option period (year four) under a previously announced, five-year contract with GenVec valued at up to $52 million for the production of HIV vaccines.

26 Sep 2009

Stelara approved by the FDA for treating psoriasis

The U.S. Food and Drug Administration today approved Stelara (ustekinumab), a biologic product for adults who have a moderate to severe form of psoriasis.

25 Sep 2009